Loading
SYNC-T Therapy SV-102 is an experimental intratumoral multi-agent immunotherapy given with partial cryolysis from Syncromune, in phase 2 trials for metastatic castration-resistant prostate cancer.
SYNC-T Therapy SV-102 (SV-102, SYNC-T) is an intratumoral multi-agent immunotherapy given with partial cryolysis (drug-device combination) from Syncromune, with Williams Cancer Foundation as sponsor of the phase 1 trial. A small part of one tumour is frozen and thawed to release tumour antigens, then SV-102 - four immune agents: abazistobart (anti-PD-1), futermestotug (anti-CTLA-4), ciltistotug (CD40 agonist) and sitmutolimod (TLR9 agonist) - is infused into the same tumour. Its furthest stage is phase 2, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in 2 studies linked below. Whether it works in people has not been established unless a trial below reports it.
A small part of one tumour is frozen and thawed to release tumour antigens, then SV-102 - four immune agents: abazistobart (anti-PD-1), futermestotug (anti-CTLA-4), ciltistotug (CD40 agonist) and sitmutolimod (TLR9 agonist) - is infused into the same tumour. Connects to PD-1, CTLA-4 and CD40.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SYNC-T Therapy SV-102" OR ABSTRACT:"SYNC-T Therapy SV-102" OR TITLE:"SV-102" OR ABSTRACT:"SV-102" OR TITLE:"SYNC-T" OR ABSTRACT:"SYNC-T") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SYNC-T Therapy SV-102, not a curated reading list.
Shares PD-1 and the tag pipeline.
Shares PD-1 and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/